Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Please Try Again {{ error }}

Send my password

SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

COSCIENS Biopharma Inc T.AEZ


Primary Symbol: T.AEZS

COSCIENS Biopharma Inc., formerly Aeterna Zentaris Inc., is a specialty biopharmaceutical company engaged in the development and commercialization of a diverse portfolio of pharmaceutical and diagnostic products, including those focused on areas of unmet medical need. Its lead product, macimorelin (Macrilen; Ghryvelin), is an oral test indicated for the diagnosis of adult growth hormone deficiency (AGHD). The Company is also engaged in the development of therapeutic assets and proprietary extraction technology, which is applied to the production of active ingredients from renewable plant resources used in cosmeceutical products (i.e., oat beta glucan and avenanthramides, which are found in skincare product brands like Aveeno and Burt’s Bees formulations) and being developed as potential nutraceuticals and/or pharmaceuticals.


TSX:AEZS - Post by User

Bullboard Posts
Comment by avispaon Nov 24, 2015 6:26am
112 Views
Post# 24318810

RE:RE:Jason Kolbert reiterated a Buy rating on shares of AEterna

RE:RE:Jason Kolbert reiterated a Buy rating on shares of AEterna
avispa wrote:
Link: https://investorshub.advfn.com/boards/read_msg.aspx?message_id=118353138


Kolbert wrote, AEterna reported 3Q with a net loss of $15M $8M were due to onetime financing costs, so $7M were operational costs. However, whats more important is that management has gone to great lengths to improve the companys capital structure, which has been suppressing valuation of a company, even with commercial products and two phase III assets in Macrilen and ZoptEC. Furthermore, The exercise of series B warrants, which were near 27M in 3Q, were keeping the companys valuation under pressure. Management was able to successfully negotiate with series B holders and effectively reduced the 27M warrants to only 800K. AEterna will look to consolidate shares and raise capital under favorable terms to continue driving pipeline and commercial assets.
Bullboard Posts